Jenburkt Pharmaceuticals share news, announcements and annual reports
NSE: JENBURPHBSE: 524731Pharmaceuticals & BiotechnologySmall Cap
Jenburkt Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1995
Last close ₹866.15up ₹12.55 (1.47%)BSE ₹860.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹853.60.
2 Nov: open ₹863.10, high ₹866.90, low ₹863.00
52-week range of BSE trades to 2 Nov 2026
₹848.05Low, 2 Nov 2026₹1,317.00High, 10 Nov 2025
- Next results date: the board meets on 3 Nov 2026 to consider: quarterly results. Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹382 Cr1,871st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 11.64
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹3.95 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 10.39
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.94
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.39%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹3.95 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 53698.1% delivered
Jenburkt Pharmaceuticals share news and announcements
653 announcements, routine notices left out, newest first. Page 9 of 14.
Jan 2018
6 Jan · Intimation of Buy back
Dec 2017
28 Dec · Updates on Buyback of Offer
Nov 2017
29 Nov · Updates on Buyback Offer
20 Nov · Results
Details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....6 Nov · Updates on Buyback Offer
Oct 2017
30 Oct · Updates
24 Oct · Certificate Under Regulation 40(9) Of SEBI (LODR) Regulations, 2015.
23 Oct · Shareholding for the Period Ended September 30, 2017
Shareholding Pattern for the Period Ended September 30, 2017. For more details, kindly Click ....
Sep 2017
14 Sep · Intimation of Buy back
9 Sep · Board approves Buyback of Equity Shares
9 Sep · Buy back
Aug 2017
Jul 2017
17 Jul · Audited Financial Statement For The Quarter And Year Ended 31St March, 2017.
12 Jul · Shareholding for the Period Ended June 30, 2017
Shareholding Pattern for the Period Ended June 30, 2017. For more details, kindly Click ....
Jun 2017
May 2017
Apr 2017
14 Apr · Compliance Certificate For The Period Ended On 31St March, 2017
14 Apr · Compliance Certificate For The Period Ended On 31St March, 2017
7 Apr · Shareholding for the Period Ended March 31, 2017
Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click ....